Cancer causes over 10 million deaths annually worldwide and remains a significant global health challenge. This study investigated advanced immunotherapy strategies, focusing on mRNA vaccines that target tumor-specific antigens to activate the immune system. We developed a novel mRNA vaccine using O,O′-dimyristyl-N-lysyl aspartate (DMKD) to improve stability and phosphatidylserine (PS) to enhance antigen presentation to immune cells. This vaccine, containing melanoma-associated antigen A3 (MAGE-A3) mRNA encapsulated within lipid nanoparticles (LNPs), was evaluated for its therapeutic potential against colorectal cancer. Our findings demonstrated that MAGE-A3 mRNA-containing DMKD-PS LNPs significantly reduced tumor size and weight, effectively combating metastatic cancer. The vaccine elicited a robust immune response, increasing specific immunoglobulin and cytokine levels without causing histotoxicity in major organs. These results confirm that the DMKD-PS-based MAGE-A3 mRNA vaccine holds promise for cancer prevention and treatment.
癌症每年在全球导致超过1000万人死亡，依然是全球健康领域的重大挑战。本研究探讨了先进的免疫治疗策略，重点关注通过靶向肿瘤特异性抗原激活免疫系统的mRNA疫苗。我们开发了一种新型mRNA疫苗，采用O,O′-二肉豆蔻酰基-N-赖氨酰天冬氨酸酯（DMKD）提升稳定性，并利用磷脂酰丝氨酸（PS）增强对免疫细胞的抗原呈递能力。该疫苗将黑色素瘤相关抗原A3（MAGE-A3）mRNA封装于脂质纳米颗粒（LNPs）中，并评估了其对结直肠癌的治疗潜力。研究结果表明，含有MAGE-A3 mRNA的DMKD-PS LNPs能显著减小肿瘤体积与重量，有效抑制转移性癌症发展。该疫苗可激发强烈的免疫反应，提升特异性免疫球蛋白及细胞因子水平，且未对主要器官造成组织毒性。这些结果证实，基于DMKD-PS的MAGE-A3 mRNA疫苗在癌症预防与治疗方面具有广阔应用前景。
Innovative Cancer Immunotherapy with MAGE-A3 mRNA Cancer Vaccines
肿瘤(癌症)患者之家